WWB
WINDWARD BIO GROUP AGPrice
Daily candles with volume.
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | None | None | No data | $0.00 |
| Next Q | None | None | No data | $0.00 |
| Current FY | None | None | No data | $0.00 |
| Next FY | None | None | No data | $0.00 |
SecBot reports
12 filings · 3 press releases · 0 bullish · 0 bearish · 12 neutral- NEUTRAL PRESS RELEASENov 16, 2026
Windward Bio Group AG closed its initial public offering of 11,838,234 common shares at $17.00 per share, including full exercise of the underwriters' option, and a concurrent $50.0 million private placement to Sanofi Foreign Participations B.V., for aggregate gross proceeds of approximately…
🔒 Fresh report (last 24h), subscribers only
- BULLISH PRESS RELEASENov 13, 2026
Qiming Venture Partners' portfolio company Windward Bio (WWB) listed on Nasdaq at $17.00 per…
Monitor Windward Bio's upcoming clinical data readouts for WIN378 (POLARIS-1 Phase 2/3 in asthma, SIRIUS Phase 2 in COPD) as key catalysts. Qiming's continued participation in the IPO signals…
- NEUTRAL EFFECTNov 13, 2026
The SEC declared effective Windward Bio Group AG's F-1 registration statement (File No…
Monitor the final IPO pricing and first-day trading performance. The concurrent Sanofi private placement signals strategic pharma interest, which may support valuation. Watch for the underwriters'…
- NEUTRAL 3Nov 12, 2026
OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC filed Form 3 initial beneficial ownership…
Monitor for the issuer's IPO filing and any subsequent Form 4 filings by OrbiMed to track changes in its stake. The large preferred share position suggests significant pre-IPO investment.
All WWB filing & press-release reports (15)
- PRESS-RELEASE reportNov 16, 2026
- PRESS-RELEASE reportNov 13, 2026
- PRESS-RELEASE reportNov 12, 2026
- EFFECT reportNov 13, 2026
- 3 reportNov 12, 2026
- 3 reportNov 12, 2026
- 3 reportNov 12, 2026
- 3 reportNov 12, 2026
- 3 reportNov 12, 2026
- 3 reportNov 12, 2026
- 3 reportNov 12, 2026
- 3 reportNov 12, 2026
- 3 reportNov 12, 2026
- 3 reportNov 12, 2026
- F-1/A reportNov 9, 2026